ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps Clinical ...
NAVIGATE II: XHANCE produced significant improvement in both co-primary outcome measures, congestion/obstruction at week four and total polyp grade at week 16 EXHANCE-12: Over one year of treatment, ...
YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (OPTN) (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today ...
XHANCE is the first and only nasal medication ever shown in Phase 3 controlled trialsto reduce exacerbations for patients with chronic sinusitis Pre-planned analysis of pooled data from the landmark ...
Xhance (fluticasone propionate) is a prescription drug that’s used to treat chronic sinusitis. Xhance comes as a nasal spray. Xhance is used in adults to treat chronic (ongoing) sinusitis (sinus ...
The FDA expanded the approval of fluticasone propionate (Xhance) nasal spray for chronic rhinosinusitis to also include treatment of adults without nasal polyps, manufacturer Optinose announced on ...
COLUMBUS, Ohio (Ivanhoe Newswire) - It’s that time of year when seasonal allergy sufferers will begin to feel the effect of grass, flowers, and plants in bloom, and people who can’t get relief from ...
COLUMBUS, Oh. - Cato Coleman is a registered dietician who works in food service, but a few years ago, his allergies became too much for him to handle. “I was having trouble breathing through my nose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback